Corticosteroids, Plasmapheresis, Argatroban, Rituximab, and Sirolimus Provided Clinical Benefit for Catastrophic Antiphospholipid Syndrome in a Patient with a History of Heparin-Induced Thrombocytopenia

We report a patient with catastrophic antiphospholipid syndrome who had significant improvement after corticosteroids, plasmapheresis, argatroban, rituximab, and sirolimus. Argatroban was used instead of heparin due to a history of heparin-induced thrombocytopenia.

[1]  C. Jurcut,et al.  Successful Treatment of Catastrophic Antiphospholipid Syndrome Using Rituximab: Case Report and Review of the Literature , 2021, Medicina.

[2]  S. Sciascia,et al.  Antiphospholipid syndrome: the need for new international classification criteria , 2021, Expert review of clinical immunology.

[3]  J. Procházková,et al.  Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review , 2021, Biomedicines.

[4]  Maryam Khaleel,et al.  Blood apheresis technologies – a critical review on challenges towards efficient blood separation and treatment , 2021, Materials Advances.

[5]  S. Levine,et al.  Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria , 2020, Arthritis care & research.

[6]  D. D'cruz,et al.  An update on the management of antiphospholipid syndrome , 2020, Therapeutic advances in musculoskeletal disease.

[7]  D. Erkan,et al.  Is there a role for immunosuppression in antiphospholipid syndrome? , 2019, Hematology. American Society of Hematology. Education Program.

[8]  G. Canaud,et al.  mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  O. Boyman,et al.  Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders , 2019, Front. Immunol..

[10]  N. Dunbar,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue , 2019, Journal of clinical apheresis.

[11]  E. Rosser,et al.  B Cells as a Therapeutic Target in Paediatric Rheumatic Disease , 2019, Front. Immunol..

[12]  P. Musette,et al.  B Cell Modulation Strategies in Autoimmune Diseases: New Concepts , 2018, Front. Immunol..

[13]  S. Knight,et al.  A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. , 2017, Transplantation reviews.

[14]  D. Erkan,et al.  Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease , 2013, Therapeutic advances in musculoskeletal disease.

[15]  Y. Shoenfeld,et al.  Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. , 2013, Autoimmunity reviews.

[16]  R. Cervera CAPS Registry , 2012, Lupus.

[17]  T. Ortel,et al.  Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.

[18]  D. Keskin,et al.  A review of the current use of rituximab in autoimmune diseases. , 2009, International immunopharmacology.

[19]  G. Espinosa,et al.  Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. , 2006, Arthritis and rheumatism.

[20]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[21]  Y. Shoenfeld,et al.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines , 2003, Lupus.

[22]  J. Piette,et al.  Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. , 2002, Arthritis and rheumatism.

[23]  K. Schulz,et al.  Descriptive studies: what they can and cannot do , 2002, The Lancet.

[24]  M. Brecher Plasma exchange: Why we do what we do , 2002, Journal of clinical apheresis.